
Sanofi and GlaxoSmithKline announced Monday that their coronavirus vaccine candidate produced powerful responses in a preliminary trial that followed an earlier setback in the vaccine’s development. In selected data that has not yet been published in a peer-reviewed journal, the vaccine “triggered strong immune response amongst adults of all age groups with 95% to 100%… read on > read on >